美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Novelion Therapeutics Inc

0.6800

0.0000

成交量：- -

成交額：- -

市值：1,334.09萬

市盈率：-0.12

高：0.6800

開：0.6800

低：0.6800

收：0.6800

52周最高：2.35

52周最低：0.5400

股本：1,961.89萬

流通股本：1,244.84萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-5.6822

每股收益(LYR):-5.7584

淨資產收益率：162.64%

總資產收益率：-5.36%

市淨率：-0.15

市盈率(LYR):-0.12

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Novelion Therapeutics Inc

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.novelion.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Novelion Therapeutics Inc.是一家專註於創新性眼科疾病類產品的研發和商業化的企業，該產品能夠解決世界範圍內患者和臨床醫師未遇到的醫學血藥。公司專註於合成類維生素A項目的研發、具有知識產權的定時藥物輸送系統的研發以及商業藥物維替泊芬（Visudyne）在美國的市場營銷，該藥可用於治療濕性年齡相關性黃斑變性。公司具有一個商業藥物，即維替泊芬（Visudyne）。該藥物採用光激發的光力學療法治療被稱為濕性年齡相關性黃斑變性（AMD）的眼科疾病，這也是在北美和歐洲50歲以上人群失明的主要原因。維替泊芬還可用於治療合併病理性近視（高度近視）（pathologic myopia）中的脈絡膜新生血管（CNV）以及假性眼睛組織胞漿菌病。維替泊芬由Novelion Therapeutics公司和諾華製藥股份公司（Novartis Pharma AG）共同研製，並在全球超過80個國家進行營銷和銷售。Novelion Therapeutics公司於1981年依照不列顛哥倫比亞省相關法律條文註冊成立。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/NVLN/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NVLN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","market":"US","secType":"STK","nameCN":"Novelion Therapeutics Inc","latestPrice":0.68,"timestamp":1570564800000,"preClose":0.68,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":12448376,"shares":19618946,"eps":-5.682162,"marketStatus":"退市","change":0,"latestTime":"05-18 07:54:56 EDT","open":0.68,"high":0.68,"low":0.68,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-5.682162,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1779111000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.68,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVLN\",,,,,undefined,":{"symbol":"NVLN","floatShares":12448376,"roa":"-5.36%","roe":"162.64%","lyrEps":-5.758398,"shares":19618946,"dividePrice":0,"high":0.68,"amplitude":0,"preClose":0.68,"low":0.68,"week52Low":0.54,"pbRate":"-0.15","week52High":2.35,"institutionHeld":0.3679,"latestPrice":0.68,"eps":-5.682162,"divideRate":0,"volume":0,"delay":0,"ttmEps":-5.682162,"open":0.68},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVLN\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-03-14","symbol":"NVLN","fiscalQuarterEnding":"2018/12","expectedEps":-0.9,"name":null,"time":"","type":"earning","dateTimestamp":1552536000000,"reportTimeType":"","actualEps":-1.03},{"market":"US","date":"2018-11-09","symbol":"NVLN","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1541739600000,"reportTimeType":"","actualEps":-1.32},{"market":"US","date":"2018-08-07","symbol":"NVLN","fiscalQuarterEnding":"2018/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1533614400000,"reportTimeType":"","actualEps":-0.64},{"market":"US","date":"2018-05-10","symbol":"NVLN","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"","actualEps":-1.76},{"market":"US","date":"2018-03-15","symbol":"NVLN","fiscalQuarterEnding":"2017/12","expectedEps":-1.58,"name":null,"time":"","type":"earning","dateTimestamp":1521086400000,"reportTimeType":"","actualEps":-1.32}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVLN\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.novelion.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.056},{"period":"3month","weight":0.0842},{"period":"6month","weight":0.1001},{"period":"1year","weight":0.2519},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Novelion Therapeutics Inc.是一家專註於創新性眼科疾病類產品的研發和商業化的企業，該產品能夠解決世界範圍內患者和臨床醫師未遇到的醫學血藥。公司專註於合成類維生素A項目的研發、具有知識產權的定時藥物輸送系統的研發以及商業藥物維替泊芬（Visudyne）在美國的市場營銷，該藥可用於治療濕性年齡相關性黃斑變性。 公司具有一個商業藥物，即維替泊芬（Visudyne）。該藥物採用光激發的光力學療法治療被稱為濕性年齡相關性黃斑變性（AMD）的眼科疾病，這也是在北美和歐洲50歲以上人群失明的主要原因。維替泊芬還可用於治療合併病理性近視（高度近視）（pathologic myopia）中的脈絡膜新生血管（CNV）以及假性眼睛組織胞漿菌病。維替泊芬由Novelion Therapeutics公司和諾華製藥股份公司（Novartis Pharma AG）共同研製，並在全球超過80個國家進行營銷和銷售。Novelion Therapeutics公司於1981年依照不列顛哥倫比亞省相關法律條文註冊成立。","exchange":"NASDAQ","name":"Novelion Therapeutics Inc","nameEN":"Novelion Therapeutics Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NVLN\",market:\"US\",,,undefined,":null}}